The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

“The approval of this treatment offers patients more options and the chance to control their disease.” “Dupixent is the first new targeted treatment ... “With this FDA decision, Dupixent ...

Women with advanced breast cancer could soon have access to a new targeted treatment on the NHS, following a decision by the National Institute for Health and Care Excellence (NICE). The tablet ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.